Biblio
“11C-CFT-PET in Presymptomatic FTDP-17: A Potential Biomarker Predicting Onset.”, J Alzheimers Dis, vol. 61, no. 2, pp. 613-618, 2018.
, “5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 573-585, 2022.
, “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “Age and its association with low insulin and high amyloid-β peptides in blood.”, J Alzheimers Dis, vol. 49, no. 1, pp. 129-37, 2016.
, “Alterations in Acrolein Metabolism Contribute to Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 571-580, 2018.
, “Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.”, Neurology, vol. 74, no. 3, pp. 201-9, 2010.
, “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
, “APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 79, no. 2, pp. 511-530, 2021.
, “Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1323-1332, 2018.
, “Association Between Serum Ceruloplasmin Specific Activity and Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1181-9, 2016.
, “Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1267-1282, 2022.
, “Association of Interleukin-6 and Interleukin-8 with Cognitive Decline in an Asian Memory Clinic Population.”, J Alzheimers Dis, vol. 92, no. 2, pp. 445-455, 2023.
, “Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1589-1598, 2018.
, “Biochemical and Radiological Markers of Alzheimer's Disease Progression.”, J Alzheimers Dis, vol. 50, no. 3, pp. 623-44, 2016.
, “Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis.”, J Alzheimers Dis, vol. 50, no. 1, pp. 161-74, 2016.
, “A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?”, J Alzheimers Dis, vol. 90, no. 3, pp. 963-966, 2022.
, “Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance.”, J Alzheimers Dis, vol. 90, no. 3, pp. 967-974, 2022.
, “Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.”, J Alzheimers Dis, vol. 50, no. 1, pp. 249-60, 2016.
, “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.
, “Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 645-651, 2018.
, “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
, “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
, “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
, “Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1107-1117, 2018.
,